Table 5. Patient categorization according to two and three spot-based clustering and disease aggressiveness.
| Patients | Cluster (288, 289) | Cluster (288, 289, 469) | Clinical classification 2 years fu | Clinical classification 5 years fu |
|---|---|---|---|---|
| MS25 | Z | OUT | PP | PP |
| MS26 | Z | B1 | M | death |
| MS27 | Z | B1 | H | H |
| MS29 | Z | B1 | H | H |
| MS44 | Z | B1 | H | H |
| MS47 | Z | B1 | H | H |
| MS28 | G | D1 | M | H |
| MS35 | Z | B1 | M | M |
| MS30 | Z | D1 | M | M |
| MS31 | G | D1 | L | M |
| MS32 | Z | D1 | M | M |
| MS33 | G | D1 | M | M |
| MS37 | G | D1 | M | M |
| MS38 | G | D1 | M | M |
| MS42 | G | D1 | M | M |
| MS43 | G | D1 | M | M |
| MS46 | G | D1 | M | M |
| MS34 | G | D1 | L | L |
| MS36 | G | D1 | L | L |
| MS45 | G | D1 | L | L |
| MS39 | G | C1 | L (B) | L (B) |
| MS40 | G | C1 | L (B) | L (B) |
| MS41 | G | C1 | lost | lost |
| MS48 | OUT | C1 | no MS | no MS |
H (high) = highly aggressive disease form, second-line approved therapies (natalizumab or fingolimod); M (moderate) = moderately aggressive disease, first-line approved therapies (interferon beta or glatiramer acetate); L (low) = scarcely aggressive or L (B) “benign” disease, no therapy. The “benign” forms of MS are characterized by no disease progression/activity without specific disease-modifying treatments for more than 10 years. Patients are ranked based on the clinical category to 5 years follow-up (fu). Fu = follow-up; OUT = outlier; lost = patients lost at follow-up.